ASPRE trial: incidence of preterm pre‐eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm

Poon, Liona C.; Rolnik, Daniel L.; Tan, Min Yi; Delgado, Juan Luis; Tsokaki, Theodora; Akolekar, Ranjit; Singh, Mandeep; Andrade, W.; Efeturk, Tunay; Jani, Jacques; Plasencia, W.; Papaioannou, George; Blàzquez, Anna; Carbone, Ilma Floriana; Wright, David; Nicolaides, Kypros H.

doi:10.1002/uog.19019

Cited by 62 publications

(55 citation statements)

References 18 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After combined screening, in some of these women the risk is increased substantially, whereas in others the risk is reduced substantially to below the background risk of the whole population. Similarly, we have reported previously that, in ACOG or NICE screen‐positive women who are screen positive by the FMF algorithm, the incidence of preterm PE is increased substantially, whereas, in the FMF screen‐negative group, the incidence is reduced to within or below background levels.…”

Section: Discussionsupporting

confidence: 77%

Screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation

Tan

Syngelaki

Poon

et al. 2018

Ultrasound in Obstet & Gyne

Self Cite

291

317

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 77%

Screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation

Tan

Syngelaki

Poon

et al. 2018

Ultrasound in Obstet & Gyne

Self Cite

291

317

View full text Add to dashboard Cite

show abstract

“…In 2360 (6.8%) pregnancies with at least two of the NICE moderate‐risk criteria, the incidence of preterm PE was 1.74% (95% CI, 1.28–2.35). In the subgroups of screen positive and screen negative by the Bayes method the incidence was 4.91% (95% CI, 3.54–6.79) and 0.42% (95% CI, 0.20–0.86), respectively, and the relative incidence was 0.085 (95% CI, 0.038–0.192) . These results provide further evidence to support risk‐based screening using biomarkers.…”

Section: First Trimester Prediction Of Pre‐eclampsiamentioning

confidence: 60%

The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre‐eclampsia: A pragmatic guide for first‐trimester screening and prevention

Poon

Shennan

Hyett

et al. 2019

Intl J Gynecology & Obste

749

628

View full text Add to dashboard Cite

“…6.1). According to the recommendation of the Foetal Medicine Foundation (FMF), BP should be measured simultaneously in both arms [102,103].…”

Section: Risk Assessment Prevention and Diagnosismentioning

confidence: 99%

Management of hypertension in pregnancy — prevention, diagnosis, treatment and long-term prognosis. A position statement of the Polish Society of Hypertension, Polish Cardiac Society and Polish Society of Gynaecologists and Obstetricians

Prejbisz¹,

Dobrowolski²,

Kosiński³

et al. 2019

Arterial Hypertension

View full text Add to dashboard Cite

Disclaimer: The position statement represent the views of the authors and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The authors and societies are not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the position statement and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the position statement fully into account when exercising their clinical judgment as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies. 118 www.ah.viamedica.pl ABPM -ambulatory blood pressure monitoring ACE-I -angiotensin-converting enzyme inhibitor AF -atrial fibrillation AFI -amniotic fluid index AFL -atrial flutter AGA -appropriate for gestational age AHI -apnea hypopnea index AKI -acute kidney injury ALT -alanine transaminase ARB -angiotensin receptor blocker ARR -aldosterone-to-renin ratio AST -aspartate aminotransferase AT -atrial tachycardia BAV -bicuspid aortic valve BMI -body mass index BNP -B-nariuretic peptide BP -blood pressure Bpm -beats per minute BPP -biophysical profile CABG -coronary artery bypass graft CAD -coronary artery disease CKD -chronic kidney disease CNS -central nervous system CoA -coarctation of the aorta CPAP -continuous positive airway pressure CPR -cerebroplacental ratio CTG -cardiotocography CV -cardiovascular DBP -diastolic blood pressure DIC -disseminated intravascular coagulation DM -diabetes mellitus ECMO -extracorporeal membrane oxygenation ECG -electrocardiography EF -ejection fraction ESC -European Society of Cardiology ESH -European Society of Hypertension EVA -early vascular ageing FDA -Food and Drug Administration FHR -foetal heart rate FIGO -International Federation of Gynaecology and Obstetrics FMD -fibromuscular dysplasia FMF -Fetal Medicine Foundation FPS -frame per second GFR -glomerular filtration rate HELLP -hemolysis, elevated liver enzymes, low platelet countuterine growth restriction IVF -in vitro fertilisation LBBB -left bundle branch block LBW -low birth weight LDH -lactate dehydrogenase LQTS -long QT syndrome LVAD -left ventricular assist device LVEF -left ventricular ejection fraction MAP -mean arterial pressure MCA -middle cerebral artery MCS -mechanical circulatory support MDT -multidisciplinary team MRA -mineralocorticoids renceptor antagonist MRAs -mineralocorticoids renceptor antagonists MRI -magnetic resonance imaging NSTEMI -non-ST elevation myocardial infarction NT-BNP -N-terminal pro-BNP NTS -non-stress-test OGTT -oral glucose tolerance test OSA -obstructive sleep apnoea p.o. -per os PA -primary aldosteronism PAPP-A -pregnancy associated placental protein PCI -percutaneous coronary intervention PE -pre-eclampsia PI -pulsatility index PlGF -placental growth factor PPCM -peripartum cardiomyopathy PPGL -pheochromocytoma a...

show abstract

ASPRE trial: incidence of preterm pre‐eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm

Cited by 62 publications

References 18 publications

Screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation

Screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation

The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre‐eclampsia: A pragmatic guide for first‐trimester screening and prevention

Management of hypertension in pregnancy — prevention, diagnosis, treatment and long-term prognosis. A position statement of the Polish Society of Hypertension, Polish Cardiac Society and Polish Society of Gynaecologists and Obstetricians

Contact Info

Product

Resources

About